Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients’ preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer

Fig. 4

Kaplan-Meier Estimate of Progression-Free Survival. Displayed are first-line (A) and second-line (B) progression-free survival in Arm A (Cap+Bev/Eve+Exe) and Arm B (Eve+Exe/Cap+Bev) in the ITT population. First-line and second-line progression-free survival were defined as the time from start of first-line / second-line therapy to progression or death due to any cause prior to start of new therapy, respectively. Patients without progression or death were censored at the date of last tumor evaluation in first-line / second-line therapy, respectively. N = number; PFS = progression-free survival; CI = confidence interval

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us